Some reports indicate that in IDH-mutant astrocytoma, homozygous deletion of CDKN2A/B is a significant molecular marker for malignant transformation and is strongly associated with poor clinical outcomes.35 This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).